Drugs / AVN944
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00273936 | Jan 2006 → ? | Hodgkins lymphoma, Waldenstrom macroglobulinemia, acute leukemia, chronic leukemia +1 | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00493441 | Jun 2007 → Dec 2009 | malignant pancreatic neoplasm | Vertex Pharmaceuticals Incorporated | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00923728 | Apr 2009 → Mar 2010 | refractory malignant neoplasm | Vertex Pharmaceuticals Incorporated | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVN944 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00493441 ↗ |
| Modality | Small molecule | “AVN944 is a small-molecule, uncompetitive inhibitor of cell proliferation.” NCT00923728 ↗ |
| Route | Oral | “oral administration” NCT00273936 ↗ |